



PerkinElmer Launches New Multilabel Plate Reader With Integrated Monochromator Options

WALTHAM, Mass. – PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced the launch of two new monochromator options for the EnVision® Multilabel Plate Reader, which is widely used by biotech, pharmaceutical and academic researchers for screening biochemical compounds in the drug discovery process. The new EnVision® technology – which will be exhibited at LabAutomation 2008, booth #427, on January 27- 30 in Palm Springs, Calif. – creates an optimized plate reader that integrates the sensitivity of filter-based system with the flexibility of a monochromator. EnVision® with Monochromator enables effortless shifting between detection technologies and applications, all on the platform that outperforms other benchtop readers on the market.

“The new monochromator options incorporated into the EnVision® system deliver unsurpassed flexibility and speed that improves hit-to-lead ratio for lead optimization,” said Dr. Richard Eglén, President, Molecular Medicine, PerkinElmer Life and Analytical Sciences. “This new technology, which is scalable to researchers' needs, demonstrates our commitment to advancing the plate reader market and the established EnVision® brand.”

EnVision® Multilabel Plate Readers are designed to deliver superior performance, regardless of label or application. The new monochromator options turn EnVision into the ultimate dual-mode instrument, capable of reading both Absorbance and Fluorescence Intensity. Available in two formats, the Absorbance Monochromator measures absorbance assays with a single monochromator, while the Fluorescence Intensity Monochromator measures absorbance and fluorescence intensity with two double-grating monochromators.

The plate reader's modular design provides a scaleable solution for laboratories' ever-changing application needs and expanding throughput demands. The Monochromator Option can be combined with other EnVision® options, including the TRF (time-resolved fluorescence) LASER, which delivers a short, sharp excitation pulse, resulting in superior signal-to-noise ratios.

The EnVision® instruments are easily integrated into robotic systems such as PerkinElmer's JANUS® Automated Workstation, and are designed to provide the greatest configuration flexibility, accepting microplates from 1 to 3456 wells. When combined with the high-precision dispenser unit and temperature control, the EnVision can perform fast kinetic measurements, enzyme assays, and numerous other cell-based drug discovery assays. EnVision is also optimized to read PerkinElmer's proprietary AlphaLISA® technology, which allows homogenous measurement of large biological molecules in complex samples such as serum and plasma, without the need for washing.

For more information about the EnVision® Multilabel Plate Reader with Monochromator Option, visit www.perkinelmer.com/platereaders.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign

operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer Inc.'s Life and Analytical Sciences business unit provides fully integrated, innovative solutions, leveraging deep scientific expertise and dedication to fulfilling customer needs to help scientists advance the pace and precision of their research and testing. It is a leading provider of diagnostic and detection instruments, reagents, software and services for advanced cellular science research and drug discovery, genetic screening, medical imaging, environmental, quality assurance and the health sciences industries.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company projects revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:

Dara Cothran

Euro RSCG Worldwide PR

(212) 367-6814

dara.cothran@eurorscg.com